ProKidney Corp., a clinical-stage biotechnology company, develops a cell therapy platform for the treatment of multiple chronic kidney diseases in the United States. Its lead product candidate, rilparencel, includes autologous selected renal cells (SRC) in Phase 3 and Phase 2 clinical studies in subjects with moderate to severe chronic kidney disease and diabetes. The company also develops a cryopreserved version of rilparencel that allows for long-term product preservation to be used in Phase 2 and 3 trials of rilparencel. ProKidney Corp. was founded in 2015 and is headquartered in Winston-Salem, North Carolina.
Metrics to compare | PROK | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipPROKPeersSector | |
---|---|---|---|---|
P/E Ratio | −6.4x | −2.5x | −0.5x | |
PEG Ratio | 1.42 | −0.02 | 0.00 | |
Price/Book | −1.0x | 2.0x | 2.6x | |
Price / LTM Sales | 3,118.3x | 678.1x | 3.3x | |
Upside (Analyst Target) | 148.2% | 187.6% | 43.5% | |
Fair Value Upside | Unlock | 9.1% | 6.3% | Unlock |